Position in RLAY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$334,379
+$156,733 QoQ
Shares Held
33,606
+108.3% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RLAY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Gotham Asset Management, LLC holds $433,918,027 across 48 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
719,545 | $81,567,621 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
105,165 | $65,574,584 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
739,273 | $57,862,897 | |
| 4 | EXEL |
Exelixis, Inc.
|
892,663 | $48,569,793 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
1,349,465 | $47,757,566 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
112,014 | $26,992,013 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
120,702 | $22,605,070 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
42,051 | $12,658,612 |
All Filings in RLAY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $334,379 | 33,606 | Shares | Sole | 2026-05-15 | |
| 2023-12-31 | $177,646 | 16,135 | Shares | Sole | 2024-02-14 | |
| 2021-09-30 | $233,132 | 7,394 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $417,930 | 11,422 | Shares | Sole | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||